Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAD044 in Hereditary Hemorrhagic Telangiectasia (HHT)
NCT05406362Phase 2Active, not recruiting
- Sponsor
- Vaderis Therapeutics AG
- Start
- Jul 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of engasertib in hereditary hemorrhagic telangiectasia (HHT), sponsored by Vaderis Therapeutics AG. Started Jul 2022; status: active, not recruiting.
02
Drugs
engasertib
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT05406362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406362.